BiotechTV - News SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
Jan 12, 2026
In this engaging discussion, Marc de Garidel, CEO of Abivax, shares insights into the promising future of obefazimod, highlighting key 2025 data and plans for 2026. He emphasizes the importance of upcoming clinical data for ulcerative colitis and Crohn's disease. Marc also addresses market pressures and M&A speculation while reassuring listeners about the safety profiles observed in trials. He describes obefazimod's unique mechanism as an immunostabilizer, offering hope for patients and optimism for forthcoming results related to fibrosis and TH17 effects.
AI Snips
Chapters
Transcript
Episode notes
From $6 To A Breakout Year
- Marc de Garidel described the company's rapid rise after July's induction results and subsequent fundraising success.
- He emphasized the team's focus remained on developing obefazimod for patients despite the hype.
Ignore Rumors; Execute The Roadmap
- Focus on delivering clinical progress rather than reacting to speculation or acquisition rumors.
- Continue executing the roadmap and prioritize patient outcomes over market noise.
French FDI Review Mirrors FTC
- Potential acquisitions of French biotech face a review by the French treasury under foreign direct investment rules.
- Marc compared the process to the U.S. FTC review but said it typically takes longer in France.